CDC) and the United States FDA announce a plan to distribute COVID-19 vaccines in their country.
We are talking about the Centers for Disease Control and Prevention and the Food and Drug Administration respectively. They are implementing a plan as part of an emergency approval for the vaccine issued by the FDA.
The FDA has taken the first step to issue the Emergency Use Authorization (ESA) for COVID 19 vaccines. Moderna mRNA, the CoVID 19 vaccine approved by the FDA on December 18, 2020 for people over 18 years of age, will be available at the end of the year.
According to a press release, beginning December 14, 2020, all COVID 19 vaccines that have received Emergency Use Authorization (EC) will be distributed in the United States.
Available COVID-19 vaccines are intended for adults. The Moderna vaccine allows vaccination of people 18 years of age or older. The Pfizer vaccine allows vaccination of people 16 years of age and older. However, people ages 16 to 17 are eligible for the vaccine against measles, mumps, rubella (MMR), and other infectious diseases.
The CDC says current evidence suggests that reinfection within 90 days of initial infection is unusual. They also suggest that vaccination could be delayed until the end of that period. The COVID-19 vaccine can be administered simultaneously with any other vaccine, so the delay makes the vaccine path difficult.
The limited number of doses means that it is not possible to specify when the vaccine will be available.
Therefore, for the moment and at the beginning, the supply of these will be limited. The scenario varies from day to day and placebo controlled trials may not be possible until the first vaccine is introduced.
The development of the mumps vaccine took four years. So how can the COVID-19 vaccine be tested so quickly and thoroughly? Why is the development of the vaccine so rapid and what are the various factors that will make it safe for use in the coming months? COVID has issued an exemption for the vaccine for children under the age of five and adults over the age of 65.
Johns Hopkins Medicine Hospital patients are being vaccinated. They are being followed to see how they evolve.
Although the supply will be initially limited, we hope to raise awareness among Spaniards about the safety and efficacy of the COVID-19 vaccine and encourage the voluntary adoption of this vaccine. Experts told Live Science that the vaccine and the Oxford vaccine also hold promise for future vaccine development. The COVID 19 vaccine will help the body develop a better understanding of which virus causes it without having to contract the disease.
It is important to note that mRNA vaccines do not contain live viruses and therefore it is not possible to develop COVID-19 by vaccination
Since we are not 100% sure that vaccinated people have an immune response in which they do not transmit the virus to others when exposed, it is likely that it is the messenger RNA (mRNA) vaccine that hits the market, which is the first of its kind. there in the United States.